Butenafine Topical Dosage
This dosage information may not include all the information needed to use Butenafine Topical safely and effectively. See additional information for Butenafine Topical.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Tinea Pedis
Apply butenafine topical cream in a quantity sufficient to cover the affected area and immediately surrounding skin once daily for 4 weeks.
Usual Adult Dose for Tinea Corporis
Apply butenafine topical cream in a quantity sufficient to cover the affected area and immediately surrounding skin once daily for 2 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Tinea Cruris
Apply butenafine topical cream in a quantity sufficient to cover the affected area and immediately surrounding skin once daily for 2 weeks, depending on the nature and severity of the infection.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Patients should use caution to avoid contact with the eyes, nose, mouth or other mucous membranes.
Use should be discontinued if irritation develops. Patients should be advised to notify their physician if irritation, redness, itching, swelling, oozing, burning, or blistering develop in the treated area.
Diagnosis of the disease should be confirmed either by culture on an appropriate medium [except Malassezia furfur (formerly Pityrosporum orbiculare)] or by direct microscopic examination of infected superficial epidermal tissue in a solution of potassium hydroxide.
Patients who are known to be sensitive to allylamine antifungals should use butenafine topical with caution since cross-reactivity may be observed.
Safety and efficacy in pediatric patients below the age of 12 years have not been determined since tinea versicolor is uncommon in patients below the age of 12 years.
Dialysis
Data not available
Other Comments
For external use only. Wash hands after applying the medication to the affected area.
Avoid contact with the eyes, nose, mouth, and other mucous membranes.
If a patient shows no clinical improvement after four weeks of treatment, the diagnosis should be redetermined.

